219 related articles for article (PubMed ID: 35781424)
1. Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease.
Ito M; Koga Y; Hachisu Y; Murata K; Sunaga N; Maeno T; Hisada T
Respir Investig; 2022 Sep; 60(5):613-624. PubMed ID: 35781424
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS/IDSA Guidelines.
Ku JH; Henkle E; Carlson KF; Marino M; Brode SK; Marras TK; Winthrop KL
Clin Infect Dis; 2023 Feb; 76(3):e1408-e1415. PubMed ID: 35607719
[TBL] [Abstract][Full Text] [Related]
3. A Rapid Screening Assay for Clarithromycin-Resistant Mycobacterium avium Complex Using Melting Curve Analysis with Nonfluorescent Labeled Probes.
Aoki A; Jinno H; Ogawa K; Nakagawa T; Inagaki T; Wajima T; Okamoto Y; Uchiya KI
Microbiol Spectr; 2023 Feb; 11(1):e0432622. PubMed ID: 36622171
[TBL] [Abstract][Full Text] [Related]
4. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
Ramirez J; Mason C; Ali J; Lopez FA
J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
[TBL] [Abstract][Full Text] [Related]
5. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
Wallace RJ; Brown-Elliott BA; McNulty S; Philley JV; Killingley J; Wilson RW; York DS; Shepherd S; Griffith DE
Chest; 2014 Aug; 146(2):276-282. PubMed ID: 24457542
[TBL] [Abstract][Full Text] [Related]
6. Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis.
Ku JH; Henkle E; Carlson KF; Marino M; Brode SK; Marras TK; Winthrop KL
Chest; 2024 May; 165(5):1058-1069. PubMed ID: 38086472
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.
Park Y; Lee EH; Jung I; Park G; Kang YA
Respir Res; 2019 Dec; 20(1):286. PubMed ID: 31852452
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.
Zweijpfenning SMH; Aarnoutse R; Boeree MJ; Magis-Escurra C; Stemkens R; Geurts B; van Ingen J; Hoefsloot W
Chest; 2024 May; 165(5):1082-1092. PubMed ID: 38040054
[TBL] [Abstract][Full Text] [Related]
9. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease.
Jhun BW; Kim SY; Moon SM; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2018 Nov; 198(10):1322-1330. PubMed ID: 29877739
[TBL] [Abstract][Full Text] [Related]
10. Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy.
Ito Y; Miwa S; Shirai M; Kanai M; Fujita K; Ohba H; Iwaizumi E; Oshima T; Kojima S; Suda T; Hayakawa H
Respir Med; 2020 Aug; 169():106025. PubMed ID: 32442113
[TBL] [Abstract][Full Text] [Related]
11. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
[TBL] [Abstract][Full Text] [Related]
12. [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].
Wagner D; Lange C
Dtsch Med Wochenschr; 2020 Aug; 145(16):1145-1151. PubMed ID: 32791550
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?
Nguyen MH; Daley CL
Clin Chest Med; 2023 Dec; 44(4):771-783. PubMed ID: 37890915
[TBL] [Abstract][Full Text] [Related]
14. [Nontuberculous Mycobacterial Pulmonary Disease - The New ATS/ERS/ESCMID/IDSA Guideline].
Wagner D; Lange C
Pneumologie; 2020 Nov; 74(11):773-779. PubMed ID: 33202438
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ
Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014
[TBL] [Abstract][Full Text] [Related]
16. Treatment for Mycobacterium avium complex lung disease.
Pan SW; Shu CC; Feng JY; Su WJ
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S67-S75. PubMed ID: 32446754
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.
Kim SM; Chong YP; Lee HJ; Shim TS; Jo KW
Microbiol Spectr; 2023 Jun; 11(3):e0474122. PubMed ID: 37022189
[TBL] [Abstract][Full Text] [Related]
18. Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review.
Diel R; Nienhaus A; Ringshausen FC; Richter E; Welte T; Rabe KF; Loddenkemper R
Chest; 2018 Apr; 153(4):888-921. PubMed ID: 29410162
[TBL] [Abstract][Full Text] [Related]
19. First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease.
Fukushima K; Kitada S; Komukai S; Kuge T; Matsuki T; Kagawa H; Tsujino K; Miki M; Miki K; Kida H
Sci Rep; 2021 Jan; 11(1):1178. PubMed ID: 33441977
[TBL] [Abstract][Full Text] [Related]
20. Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001-2013.
Brode SK; Chung H; Campitelli MA; Kwong JC; Marchand-Austin A; Winthrop KL; Jamieson FB; Marras TK
Emerg Infect Dis; 2019 Jul; 25(7):1271-80. PubMed ID: 31215507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
